The CTRB1/2 locus affects diabetes susceptibility and treatment via the 
incretin pathway

t Hart, L. M.; Fritsche, A.; Nijpels, G.; van Leeuwen, N.; Donnelly, L. A.; Dekker, J. M.; Alssema, M.; Fadista, J.; Carlotti, F.; Gjesing, A. P.; Palmer, C. N.; van Haeften, T. W.; Herzberg-Schafer, S. A.; Simonis-Bik, A. M.; Houwing-Duistermaat, J. J.; Helmer, Q.; Deelen, J.; Guigas, B.; Hansen, T.; Machicao, F.; Willemsen, G.; Heine, R. J.; Kramer, M. H.; Holst, J. J.; de Koning, E. J.; Haring, H. U.; Pedersen, O.; Groop, L.; de Geus, E. J.; Slagboom, P. E.; Boomsma, D. I.; Eekhoff, E. M.; Pearson, E. R.; Diamant, M.

doi:10.2337/db13-0227

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway

MPS-Authors

/persons/resource/persons276058

Deelen, J.
Deelen – Genetics and Biomarkers of Human Ageing, Research Groups, Max Planck Institute for Biology of Ageing, Max Planck Society;

External Resource

https://www.ncbi.nlm.nih.gov/pubmed/23674605
(Any fulltext)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

t Hart, L. M., Fritsche, A., Nijpels, G., van Leeuwen, N., Donnelly, L. A., Dekker, J. M., et al. (2013). The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes, 62(9), 3275-81. doi:10.2337/db13-0227.

Cite as: https://hdl.handle.net/21.11116/0000-000B-6E77-5

Abstract

The incretin hormone glucagon-like peptide 1 (GLP-1) promotes glucose homeostasis and enhances beta-cell function. GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit the physiological inactivation of endogenous GLP-1, are used for the treatment of type 2 diabetes. Using the Metabochip, we identified three novel genetic loci with large effects (30-40%) on GLP-1-stimulated insulin secretion during hyperglycemic clamps in nondiabetic Caucasian individuals (TMEM114; CHST3 and CTRB1/2; n = 232; all P </= 8.8 x 10(-7)). rs7202877 near CTRB1/2, a known diabetes risk locus, also associated with an absolute 0.51 +/- 0.16% (5.6 +/- 1.7 mmol/mol) lower A1C response to DPP-4 inhibitor treatment in G-allele carriers, but there was no effect on GLP-1 RA treatment in type 2 diabetic patients (n = 527). Furthermore, in pancreatic tissue, we show that rs7202877 acts as expression quantitative trait locus for CTRB1 and CTRB2, encoding chymotrypsinogen, and increases fecal chymotrypsin activity in healthy carriers. Chymotrypsin is one of the most abundant digestive enzymes in the gut where it cleaves food proteins into smaller peptide fragments. Our data identify chymotrypsin in the regulation of the incretin pathway, development of diabetes, and response to DPP-4 inhibitor treatment.